Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Boguniewicz

Showing results (141-150 of 160) with videos related to

Pageof 16
Sort By:
The Journal of Allergy and Clinical Immunology. in Practice|August 21, 2022
Dietary Elimination for the Treatment of Atopic Dermatitis: A Systematic Review and Meta-AnalysisPaul Oykhman, Jared Dookie, Husam Al-Rammahy, et al.
Journal of the American Academy of Dermatology|July 16, 2016
Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adultsAmy S Paller, Wynnis L Tom, Mark G Lebwohl, et al.
The Journal of Allergy and Clinical Immunology. in Practice|January 16, 2021
Dupilumab Improves Asthma and Sinonasal Outcomes in Adults with Moderate to Severe Atopic DermatitisMark Boguniewicz, Lisa A Beck, Lawrence Sher, et al.
Pediatric Dermatology|February 21, 2025
Efficacy and Safety of Once-Daily Roflumilast Cream 0.05% in Pediatric Patients Aged 2-5 Years With Mild-to-Moderate Atopic Dermatitis (INTEGUMENT-PED): A Phase 3 Randomized Controlled TrialLawrence F Eichenfield, Rocco Serrao, Vimal H Prajapati, et al.
Pediatric Allergy and Immunology : Official Publication of the European Society of Pediatric Allergy and Immunology|January 6, 2015
Pimecrolimus in atopic dermatitis: consensus on safety and the need to allow use in infantsThomas Luger, Mark Boguniewicz, Warner Carr, et al.
The Journal of Allergy and Clinical Immunology|June 14, 2023
Rapid reduction in Staphylococcus aureus in atopic dermatitis subjects following dupilumab treatmentEric L Simpson, Patrick M Schlievert, Takeshi Yoshida, et al.
The Journal of Allergy and Clinical Immunology|July 4, 2006
Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus ReportCezmi A Akdis, Mübeccel Akdis, Thomas Bieber, et al.
The Journal of Allergy and Clinical Immunology|December 18, 2010
Tight junction defects in patients with atopic dermatitisAnna De Benedetto, Nicholas M Rafaels, Laura Y McGirt, et al.
Journal of the American Academy of Dermatology|June 24, 2020
Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trialAmy S Paller, Elaine C Siegfried, Diamant Thaçi, et al.
JAMA Dermatology|November 7, 2019
Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical TrialEric L Simpson, Amy S Paller, Elaine C Siegfried, et al.
Pageof 16

Showing results (141-150 of 160) with videos related to

Sort By:
Pageof 16
The Journal of Allergy and Clinical Immunology. in Practice|August 21, 2022
Dietary Elimination for the Treatment of Atopic Dermatitis: A Systematic Review and Meta-AnalysisPaul Oykhman, Jared Dookie, Husam Al-Rammahy, et al.
Journal of the American Academy of Dermatology|July 16, 2016
Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adultsAmy S Paller, Wynnis L Tom, Mark G Lebwohl, et al.
The Journal of Allergy and Clinical Immunology. in Practice|January 16, 2021
Dupilumab Improves Asthma and Sinonasal Outcomes in Adults with Moderate to Severe Atopic DermatitisMark Boguniewicz, Lisa A Beck, Lawrence Sher, et al.
Pediatric Dermatology|February 21, 2025
Efficacy and Safety of Once-Daily Roflumilast Cream 0.05% in Pediatric Patients Aged 2-5 Years With Mild-to-Moderate Atopic Dermatitis (INTEGUMENT-PED): A Phase 3 Randomized Controlled TrialLawrence F Eichenfield, Rocco Serrao, Vimal H Prajapati, et al.
Pediatric Allergy and Immunology : Official Publication of the European Society of Pediatric Allergy and Immunology|January 6, 2015
Pimecrolimus in atopic dermatitis: consensus on safety and the need to allow use in infantsThomas Luger, Mark Boguniewicz, Warner Carr, et al.
The Journal of Allergy and Clinical Immunology|June 14, 2023
Rapid reduction in Staphylococcus aureus in atopic dermatitis subjects following dupilumab treatmentEric L Simpson, Patrick M Schlievert, Takeshi Yoshida, et al.
The Journal of Allergy and Clinical Immunology|July 4, 2006
Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus ReportCezmi A Akdis, Mübeccel Akdis, Thomas Bieber, et al.
The Journal of Allergy and Clinical Immunology|December 18, 2010
Tight junction defects in patients with atopic dermatitisAnna De Benedetto, Nicholas M Rafaels, Laura Y McGirt, et al.
Journal of the American Academy of Dermatology|June 24, 2020
Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trialAmy S Paller, Elaine C Siegfried, Diamant Thaçi, et al.
JAMA Dermatology|November 7, 2019
Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical TrialEric L Simpson, Amy S Paller, Elaine C Siegfried, et al.
Pageof 16